"Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1)." Investor Relations
Do not crush, split or chew your tablet
Data Validation and Update Cycle: Findings were validated through expert review and aligned with recent treatment, approval, and usage data
(2024) 13:e230241
Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A
At a Glance What It Is & Composition Tirzepatide is a single 39-amino-acid synthetic peptide engineered as a dual agonist : one molecule that binds and activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor